Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Dyne Therapeutics, Inc. Common Stock (DYN)

Pharmaceutical Preparations

https://www.dyne-tx.com

Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.

1560 TRAPELO ROAD
WALTHAM, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/17/2020

Market Cap

4,545,153,270

Shares Outstanding

61,380,000

Weighted SO

78,533,648

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

STOK --.--%

PLRX --.--%

CYTK --.--%

RVMD --.--%

EWTX --.--%

CGEM --.--%

MLYS --.--%

DICE --.--%

KRTX --.--%

Beta

1.0710

Last Div

0.0000

Range

6.4-46.39

Chg

-0.4700

Avg Vol

1287656

Mkt Cap

4545153270

Exch

NASDAQ

Country

US

Phone

781 786 8230

DCF Diff

43.7815

DCF

1.5785

Div Yield

0.0000

P/S

1199.8821

EV Multiple

-14.6914

P/FV

5.4023

Div Yield %

0.0000

P/E

-16.2572

PEG

0.6714

Payout

0.0000

Current Ratio

26.6299

Quick Ratio

26.6299

Cash Ratio

20.4415

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

353.5821

CCC

-353.5821

Gross Margin

0.4852

Op Margin

-71.5628

Pretax Margin

-68.0040

Net Margin

-68.0040

Eff Tax Rate

-0.0035

ROA

-0.3119

ROE

-0.6885

ROCE

-0.3405

NI/EBT

1.0000

EBT/EBIT

0.9503

EBIT/Rev

-71.5628

Debt Ratio

0.0311

D/E

0.0332

LT Debt/Cap

0.0263

Total Debt/Cap

0.0321

Int Coverage

-160.4973

CF/Debt

-8.5163

Equity Multi

1.0654

Rec Turnover

0.0000

Pay Turnover

1.0323

Inv Turnover

0.0000

FA Turnover

0.1197

Asset Turnover

0.0046

OCF/Share

-2.3675

FCF/Share

-2.3815

Cash/Share

8.4192

OCF/Sales

-57.8176

FCF/OCF

1.0059

CF Coverage

-8.5163

ST Coverage

-45.8282

CapEx Coverage

-168.8612

Div&CapEx Cov

-168.8612

P/BV

5.4023

P/B

5.4023

P/S

1199.8821

P/E

-16.2572

P/FCF

-20.6307

P/OCF

-19.1214

P/CF

-19.1214

PEG

0.6714

P/S

1199.8821

EV Multiple

-14.6914

P/FV

5.4023

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Mar 16, 23:00 Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months GlobeNewswire Inc. May 22, 00:39 Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 05, 07:30 Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. Jan 04, 22:46 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 04, 22:46 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 04, 22:46 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 04, 22:46 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 04, 22:46 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 04, 22:46 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock GlobeNewswire Inc. Jan 03, 16:25 Dyne Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc. Jan 03, 06:30 Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCEâ„¢ Platform in Developing Therapeutics for Rare Muscle Diseases MarketWatch Nov 30, 12:18 What ETF investors need to know before adding gold to their portfolios Zacks Investment Research Nov 01, 18:40 Q2 Holdings (QTWO) Tops Q3 Earnings Estimates GlobeNewswire Inc. Oct 30, 07:30 Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones

Revenue Product Segmentation